ASX:NAB
ASX:NABBanks

NAB (ASX:NAB) Valuation Check as New $60b Affordable Housing Push Takes Shape

National Australia Bank (ASX:NAB) has turned heads with a new strategic push into affordable housing, committing construction finance for three Assemble projects worth about $500 million as part of a broader $60 billion housing financing ambition by 2030. See our latest analysis for National Australia Bank. That affordable housing push comes after a steady run for the bank, with the latest A$41.38 share price sitting on an 11.12 percent year to date share price return and a powerful 121.39...
ASX:SHA
ASX:SHAConstruction

3 ASX Stocks That May Be Trading Up To 49.1% Below Intrinsic Value Estimates

The Australian stock market has faced challenges this year, with the ASX200 underperforming compared to a basket of its peers despite some sectors like materials and real estate showing resilience. In such an environment, identifying undervalued stocks can be crucial for investors seeking potential opportunities, as these stocks may offer value relative to their intrinsic worth amidst broader market fluctuations.
ASX:STK
ASX:STKMetals and Mining

3 ASX Penny Stocks With Market Caps Reaching A$900M

The Australian stock market has faced challenges recently, with the ASX200 underperforming compared to its global peers despite a US Fed Rate Cut. In such conditions, investors often look towards penny stocks as a potential avenue for growth. Although the term "penny stocks" may seem outdated, these smaller or newer companies can offer opportunities when they possess strong financials and clear growth prospects.
ASX:ILU
ASX:ILUMetals and Mining

Iluka Resources (ASX:ILU): Valuation Check After Withdrawing 2025 Synthetic Rutile Production Guidance

Iluka Resources (ASX:ILU) has been back in the spotlight after scrapping its 2025 synthetic rutile production guidance. The company cited an unresolved contract with a key UK customer that rattled investors and amplified recent downgrades. See our latest analysis for Iluka Resources. The guidance withdrawal has accelerated a pullback that was already forming, with a 7 day share price return of minus 8.87 percent and a 30 day share price return of minus 11.94 percent. However, the year to date...
ASX:WBC
ASX:WBCBanks

Westpac (ASX:WBC): Rethinking Valuation After Governance Tensions, Climate Scrutiny and Recent Operational Disruptions

Westpac Banking (ASX:WBC) is back in the spotlight after a rare governance protest vote, renewed pressure over its fossil fuel lending, and a recent eftpos outage that briefly disrupted thousands of customers. See our latest analysis for Westpac Banking. Despite this mix of governance tension, climate scrutiny and operational hiccups, Westpac’s A$38.26 share price still sits on a robust year to date share price return of 18.05 percent, underpinned by a strong 1 year total shareholder return...
ASX:JHX
ASX:JHXBasic Materials

How Investors May Respond To James Hardie Industries (ASX:JHX) Revamping North American Leadership Ranks

Earlier this week, James Hardie Industries appointed Jonathan Skelly as President and General Manager of its North America Building Products Group and promoted long-time executive John Madson to Chief Sales Officer, while North America President Sean Gadd chose to leave the company. The leadership reshuffle hands James Hardie’s largest market to an external hire with deep experience at AZEK and Grainger, paired with an insider sales leader who has spent over two decades building the firm’s...
ASX:WIA
ASX:WIAMetals and Mining

3 ASX Penny Stocks With Market Caps Under A$2B

Australian shares are poised for a robust start, with a projected 0.75% increase following the Federal Reserve's decision to trim U.S. rates for the third consecutive time. In this context, penny stocks—despite their somewhat outdated moniker—remain an intriguing investment area due to their potential for significant returns when backed by solid financials. This article explores three ASX penny stocks that exhibit strong financial foundations and could offer investors hidden value and growth...
ASX:CUV
ASX:CUVBiotechs

Clinuvel Pharmaceuticals (ASX:CUV): Valuation Check After Vallaurix Expansion to Boost Peptide Drug Development

Clinuvel Pharmaceuticals (ASX:CUV) is in the spotlight after unveiling a major expansion of its Vallaurix innovation hub in Singapore. The company has announced a five year push backed by the Economic Development Board to accelerate advanced peptide drug development. See our latest analysis for Clinuvel Pharmaceuticals. The market seems to be warming to that strategy, with a 30 day share price return of 17.15% and a 90 day gain of 21.11%. However, the five year total shareholder return...